Predictors of major bleeding in peri-procedural anticoagulation management

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 2, 2012, Pages 261-267

  Tafur, A J ^a   McBane, R ^a   Wysokinski, W E ^a   Litin, S ^a   Daniels, P ^a   Slusser, J ^a   Hodge, D ^a   Beckman, M G ^b   Heit, J A ^a  

^a MAYO CLINIC   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Anticoagulation; Bleeding; Low molecular weight heparin; Surgery; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; INVASIVE PROCEDURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PERIPHERAL ARTERY THROMBOEMBOLISM; PREDICTOR VARIABLE; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; UNSTABLE ANGINA PECTORIS;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MINNESOTA; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TIME FACTORS; WARFARIN;

EID: 84856558621     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04572.x     Document Type: Article

References (21)

1. Waterman AD, Banet G, Milligan PE, Frazier A, Verzino E, Walton B, Gage BF. Patient and physician satisfaction with a telephone-based anticoagulation service. J Gen Intern Med 2001; 16: 460-3.
2. Daniels PR, McBane RD, Litin SC, Ward SA, Hodge DO, Dowling NF, Heit JA. Peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. Thromb Res 2009; 124: 300-5.
3. Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AG, Bates SM, Desjardins L, Douketis J, Kahn SR, Solymoss S, Wells PS. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110: 1658-63.
4. Wysokinski WE, McBane RD, Daniels PR, Litin SC, Hodge DO, Dowling NF, Heit JA. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc 2008; 83: 639-45.
5. Spyropoulos AC, Turpie AG, Dunn AS, Spandorfer J, Douketis J, Jacobson A, Frost FJ; REGIMEN Investigators. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006; 4: 1246-52.
6. McBane RD, Wysokinski WE, Daniels PR, Litin SC, Slusser J, Hodge DO, Dowling NF, Heit JA. Periprocedural anticoagulation management of patients with venous thromboembolism. Arterioscler Thromb Vasc Biol 2010; 30: 442-8.
7. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost 2007; 5: 2211-8.
8. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-8.
9. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 299S-339S.
10. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost, 2005; 3: 692-4.
11. Hammerstingl C, Schmitz A, Fimmers R, Omran H. Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry. Cardiovasc Ther 2009; 27: 230-8.
12. Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost 2005; 94: 528-31.
13. Jaffer AK, Brotman DJ, Bash LD, Mahmood SK, Lott B, White RH. Variations in perioperative warfarin management: outcomes and practice patterns at nine hospitals. Am J Med 2010; 123: 141-50.
14. Kovac Z, Kovac M, Mitic G, Antonijevic N. The oncology treatment of patients who use oral anticoagulants is connected with high risk of bleeding complications. J Thromb Thrombolysis 2010; 30: 210-4.
15. Tafur A, Wysokinski WE, McBane RD, Wolny E, Sutkowska E, Litin SC, Daniels PR, Slusser JP, Hodge DO, Heit JA. Three month cumulative incidence of thromboembolism and bleeding after periprocedural anticoagulation management of patients with active cancer. Blood, 2009; 114: 491.
16. Blacker DJ, Wijdicks EF, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology 2003; 61: 964-8.
17. Jaffer AK, Ahmed M, Brotman DJ, Bragg L, Seshadri N, Qadeer MA, Klein A. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis 2005; 20: 11-6.
18. Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost, 2009; 102: 268-78.
19. van Leeuwen Y, Rombouts EK, Kruithof CJ, van der Meer FJ, Rosendaal FR. Improved control of oral anticoagulant dosing: a randomized controlled trial comparing two computer algorithms. J Thromb Haemost 2007; 5: 1644-9.
20. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
21. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: the Eighth ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2008; 133: 381S-453S.